CaNCURE was established in 2014, with a $1.15M training grant from the NCI, to train undergraduate students in research at the interface of nanotechnology, cancer biology, and medicine. The program provides a hands-on research experience and one-on-one mentoring by leading Boston researchers in cancer nanomedicine. This program is specifically designed for engineers and scientists with an interest in performing cancer or nanomedicine research.
Northeastern University is a world-leader in practice-oriented undergraduate education. CaNCURE combines NEU’s co-op model with the extensive research infrastructure at NEU and Dana-Farber/Harvard Cancer Center to create a training program specialized in cancer nanomedicine.
By providing trainees with a rich set of opportunities to develop scientific and professional skills, we hope to encourage the next generation of scientists and clinicians to pursue a career in cancer research or cancer medicine.
Northeastern University, founded in 1898 as a higher education institution to educate working class communities, is a leader in interdisciplinary research, urban engagement, and the integration of classroom learning with real-world experience. The University offers a comprehensive range of graduate programs including 90 masters and professional degrees, and 25 doctoral degrees, to 3500 graduate students in six colleges, eight graduate schools, and two part-time divisions. Approximately 15.6% of the student body is comprised of underrepresented minorities (URM).
Dana-Farber/Harvard Cancer Center (DF/HCC) is a research consortium of more than 1,100 cancer researchers across five Boston academic medical institutions—Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital—and two Harvard Schools—the Harvard Medical School and the Harvard T.H. Chan School of Public Health. DF/HCC, a NCI-designated comprehensive cancer center funded through a Cancer Center Support Grant awarded by the NCI, is one of the largest cancer research consortia in the country.
DF/HCC is committed to maximizing the impact of its research for cancer patients and ultimately realizing a world without cancer. DF/HCC was founded to integrate and build upon the collective talent and resources of the Harvard cancer research community. Researchers combine their scientific strengths to create a rich, collaborative environment that transcends institutional borders.